Non-small cell lung cancer · line 2 · Adagrasib monotherapy (KRYSTAL-1) — 2L+ KRAS G12C+ NSCLC

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-ADAGRASIB-NSCLC`

ID	`IND-NSCLC-2L-KRAS-G12C-ADAGRASIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-KRYSTAL1-JANNE-2022` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track for KRAS G12C+ NSCLC with active brain metastases. KRYSTAL-12 phase-3 confirmatory trial ongoing.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L